Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
2019 · Leukemia · 447 citations
https://doi.org/10.1038/s41375-019-0602-x
C
Carolyn Owen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
229
Papers
11.1K
Citations
40
h-index
89
i10-index
Carolyn Owen is an academic researcher from University of Calgary. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 40, co-authored 195 publications.
ORCID: 0000-0003-4110-1708Papers by this author
worksThe complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
2020 · Nature Communications · 115 citations
https://doi.org/10.1038/s41467-020-14829-5
Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
2019 · Current Oncology · 96 citations
https://doi.org/10.3747/co.26.4345
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 · New England Journal of Medicine · 76 citations
https://doi.org/10.1056/nejmoa2409804
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
2021 · Leukemia · 75 citations
https://doi.org/10.1038/s41375-021-01241-1
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
2022 · PharmacoEconomics - Open · 12 citations
https://doi.org/10.1007/s41669-022-00375-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat